Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017–2018), and on clonal distribution of MRSA

Riccobono, Eleonora; Giani, Tommaso; Baldi, Giulia; Arcangeli, Sophie; Antonelli, Alberto; Tellone, Valeria; Vecchio, A. Del; Joannon, Alessandra Capezzone de; Rossolini, Gian María

doi:10.1016/j.ijantimicag.2021.106503

Cited by 12 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A screen of 3,929 clinical isolates of MRSA and MSSA from 12 different countries against linezolid, tigecycline and vancomycin reported MIC 50 and MIC 90 values ( Karlowsky et al., 2017 ) that were either identical, or within one MIC dilution factor, to those reported in this study. Similarly, another screen against 756 MRSA and MSSA clinical isolates obtained from across Europe and Russia against the same three antibiotics ( Riccobono et al., 2022 ) also reported similar MIC 50 and MIC 90 ranges. The manuscript by Riccobono et al.…”

Section: Discussionmentioning

confidence: 74%

“…Similarly, another screen against 756 MRSA and MSSA clinical isolates obtained from across Europe and Russia against the same three antibiotics ( Riccobono et al., 2022 ) also reported similar MIC 50 and MIC 90 ranges. The manuscript by Riccobono et al. (2022) also report MIC 50 and MIC 90 values for the same three antibiotics against 218 Coagulase negative Staphylococcus species isolates, which are also either identical, or within one MIC dilution factor, to those reported in this study.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates

Rhys-Williams,

Galvin,

Love

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of Staphylococcus aureus in the nasal cavity to prevent post-operative staphylococcal infections. This study reports the minimum inhibitory concentration (MIC) of XF-73 in comparison to 22 antibiotics against a panel of >2,500 clinical isolates composed of 16 different Coagulase-positive and -negative Staphylococcus species from 33 countries. XF-73 was found to be effective against all isolates tested, with MICs ranging between ≤0.12 – 4 µg/ml (MIC50 and MIC90 values of 0.5 and 1 µg/ml respectively). XF-73 was found to be equally effective against antibiotic resistant isolates as antibiotic sensitive isolates, with no impact of pre-existing antibiotic resistance mechanisms to cell wall synthesis inhibitors (β-lactams, carbapenems, glycopeptides and cephalosporins), protein synthesis inhibitors (oxazolidinones, macrolides and tetracyclines), DNA synthesis inhibitors (fluoroquinolones) and a folate synthesis inhibitor. The panel selected also included examples of multidrug-resistant S. aureus isolates and, in all cases, the XF-73 MIC ranges were found to be similar against each of these groups. This dataset expands the knowledge of the breadth of activity of this novel antibacterial against a wide range of global S. aureus isolates and supports the potential utility of XF-73 for the treatment of patients who are S. aureus nasal carriers. Similar results were also obtained for multidrug-resistant isolates of other Staphylococcus species included in the study and collectively support the continued clinical development of XF-73 as an effective anti-staphylococcal drug.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 74%

Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates

Rhys-Williams,

Galvin,

Love

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…97.4% and 92.3% of MRSA were susceptible to gentamicin and levofloxacin, respectively, which was significant when compared to findings by Riccobono et al (75%, 23.3%, with p = 0.002 and <0.001, respectively), but significantly low susceptibility to erythromycin (7.7% vs 29%, p = 0.005). 36 The reason for this difference may have been due to selective pressures of this bacteria with different geographical distribution to the drug.…”

Section: Discussionmentioning

confidence: 99%

Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus

Liang¹,

Hu²,

Fu³

et al. 2023

IDR

View full text Add to dashboard Cite

To investigate the molecular epidemiology of Staphylococcus aureus (S. aureus) isolated from patients in the Yellow River Delta region and to construct antibiotic resistance profiles in different genetic backgrounds. Methods: Antibiotics susceptibility testing, staphylococcal protein A (spa) typing and accessory gene regulator (agr) typing were performed for all the 204 strains. Isolates with the positive mecA gene and heterogeneous vancomycin-intermediate S. aureus (hVISA) were subjected to multilocus sequence typing (MLST) and Staphylococcal chromosomal cassettes mec (SCCmec) typing. Results: Thirty-nine MRSA strains were identified by mecA gene. Twenty-two hVISA isolates including 9 MRSA and 13 methicillinsensitive S. aureus (MSSA) strains were confirmed, the rest isolates (n = 182) were vancomycin-susceptible S. aureus (VSSA). 94.9% of MRSA and 63.6% of hVISA belonged to agrI. Fifty-seven distinct spa types including 5 novel types were mainly t309 (30.9%), t078 (11.8%) and t437 (11.8%). Fourteen sequence types (STs) containing 3 new STs were classified into 3 clone complexes (CCs) and 7 singletons among MRSA and hVISA isolates. Most MRSA isolates (87.2%) belonged to type Ⅳ SCCmec. Conclusion:The predominant genotype among MRSA population was ST59-t437-agrI-IVa (53.8%), followed by ST72-t2431-agr I-IVF (15.4%). ST72 and CC5 (ST5/965/7197) were the most common hVISA clones. Both CC59 (ST59/7437) and ST72 clones were resistant to erythromycin and clindamycin among MRSA population. Strains of MSSA with phenotypic hVISA (MS-hVISA) exhibited a striking genetic diversity accompanied by the diversification of drug resistance patterns.

show abstract

“…Dalbavancin is synthesized from A40926 by a three-step sequence, resulting in amidation of the C-terminus with 3-(dimethylamino)-1-propylamine . Dalbavancin exhibits potent activity toward Gram-positive strains, including MRSA (MIC = 0.06–1 μg/mL), streptococci (MIC ≤0.03 μg/mL), and VanB-type VRE (MIC ≤0.03–4 μg/mL). ,− …”

Section: Clinically Used Semisynthetic Lipoglycopeptide Antibioticsmentioning

confidence: 99%

Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014–2022

2022

View full text Add to dashboard Cite

The accelerated appearance of drug-resistant bacteria poses an ever-growing threat to modern medicine’s capacity to fight infectious diseases. Gram-positive species such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae continue to contribute significantly to the global burden of antimicrobial resistance. For decades, the treatment of serious Gram-positive infections relied upon the glycopeptide family of antibiotics, typified by vancomycin, as a last line of defense. With the emergence of vancomycin resistance, the semisynthetic glycopeptides telavancin, dalbavancin, and oritavancin were developed. The clinical use of these compounds is somewhat limited due to toxicity concerns and their unusual pharmacokinetics, highlighting the importance of developing next-generation semisynthetic glycopeptides with enhanced antibacterial activities and improved safety profiles. This Review provides an updated overview of recent advancements made in the development of novel semisynthetic glycopeptides, spanning the period from 2014 to today. A wide range of approaches are covered, encompassing innovative strategies that have delivered semisynthetic glycopeptides with potent activities against Gram-positive bacteria, including drug-resistant strains. We also address recent efforts aimed at developing targeted therapies and advances made in extending the activity of the glycopeptides toward Gram-negative organisms.

show abstract

Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017–2018), and on clonal distribution of MRSA

Cited by 12 publications

References 36 publications

Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates

Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates

Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus

Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014–2022

Contact Info

Product

Resources

About